Search
for
Sort by
Research 571–600 of 685
- The Role of the Orthognathic Surgeon in Facial Feminization Surgery
- Providing mesotherapy to prevent and treat hair loss in aesthetic practice
- Minimal systemic exposure of a new topical triazole antifungal, efinaconazole 10% solution, in patients with severe onychomycosis following 28-day treatment
- Miniflap Hair Restoration
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
- Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
- Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
- Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia
- Orthostatic symptoms in women treated with low-dose oral minoxidil in the absence of overt hypotension: Implications for clinical practice
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Topoisomerase‐Interacting Agents
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
- Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
- Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
- 5PSQ-117 Effectiveness of baricitinib in alopecia areata
- Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- β1 Integrins with Individually Disrupted Cytoplasmic NPxY Motifs Are Embryonic Lethal but Partially Active in the Epidermis
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- The treatment of polycystic ovary syndrome.
- Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics
- Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment
- A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
- Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
- Accumulations of Ca/P in the core of hairs from Taklamakan desert mummies
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Why Odds Ratios Can Be Tricky Statistics